EirGenix Secures Commercial License Agreement for Second HER2 Biosimilar, EG1206A

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 12 2025

0mins

Source: Yahoo Finance

Licensing Agreement: EirGenix Inc. has signed a second global exclusive licensing agreement with Sandoz AG for its breast cancer biosimilar, EG1206A, which covers all territories except certain Asian countries. The agreement includes up to USD 152 million in payments and profit-sharing upon product launch.
Regulatory Progress: EG1206A has completed its pharmacokinetic clinical study and received positive feedback from the U.S. FDA and EMA, qualifying for an abbreviated development pathway that waives Phase III trials, marking a significant milestone in EirGenix's biosimilar development.
Market Potential: With approximately 2.3 million breast cancer patients globally, and a significant portion diagnosed with HER2-positive disease, the combination therapy of Trastuzumab and Pertuzumab is the current standard of care, indicating strong market potential for EG1206A.
EirGenix's Growth: EirGenix is expanding its biosimilar pipeline and CDMO services, leveraging its technical expertise and production capacity to attract international pharmaceutical partnerships, positioning itself as a key player in the global biosimilar market.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.